Impact of complete cytogenetic response on survival in patients with myelodysplastic syndromes.

被引：0
|
作者：
Urrutia, Samuel
Sasaki, Koji
Kantarjian, Hagop M.
Jabbour, Elias
Chien, Kelly Sharon
Hammond, Danielle
Bueso-Ramos, Carlos E.
Khoury, Joseph
Patel, Keyur P.
Montalban-Bravo, Guillermo
Wei, Yue
Colla, Simona
Short, Nicholas James
Daver, Naval Guastad
Borthakur, Gautam
Kadia, Tapan M.
Pierce, Sherry
Wierda, William G.
Garcia-Manero, Guillermo
机构：
[1] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6567
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Circulating dendritic cells of the patients with myelodysplastic syndromes.
    Shao, Zonghong
    Wang, Huaquan
    Xing, Limin
    Fu, Rong
    Tu, Fengmei
    BLOOD, 2007, 110 (11) : 221B - 221B
  • [22] Delayed responses to thalidomide in patients with myelodysplastic syndromes.
    Lisak, LA
    Little, L
    Dean, L
    Ekbal, M
    duRandt, M
    Hussain, M
    Kaistha, V
    Raza, A
    BLOOD, 2000, 96 (11) : 261B - 261B
  • [23] Biologic characteristics of patients with hypocellular myelodysplastic syndromes.
    Goyal, R
    Qawi, H
    Ali, SI
    Dar, S
    Mundle, S
    Ahmed, B
    Quadri, M
    Naseer, OB
    Andrews, C
    Shetty, V
    Mativi, B
    Altampallam, K
    Lisak, L
    Loew, J
    Venugopal, P
    Gezer, S
    Robin, E
    Rifkin, S
    Raza, A
    BLOOD, 1998, 92 (10) : 629A - 629A
  • [24] Abnormal lipid profiles in patients with myelodysplastic syndromes.
    Allampallam, K
    Dutt, D
    Nair, C
    Shetty, V
    Mundle, S
    Lisak, L
    Andrews, C
    Ahmed, B
    Mazzone, L
    Zorat, F
    Borok, R
    Muzammil, M
    Akber, A
    Gundroo, A
    Ansaarie, I
    Raza, A
    BLOOD, 1999, 94 (10) : 282B - 282B
  • [25] Disparities in receipt of complete diagnostic evaluation to confirm myelodysplastic syndromes.
    Mukherjee, Sudipto
    Dong, Weichuan
    Statler, Abby
    Koroukian, Siran M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine
    Gangatharan, Shane A.
    Carney, Dennis A.
    Campbell, Lynda J.
    Prince, H. Miles
    Kenealy, Melita K.
    Seymour, John F.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2011, 87 (02) : 186 - 188
  • [27] Impact of Cytogenetic Abnormalities and Cytogenetic Response to Hypomethylating Agents (HMAs) in Patients (pts) with Lower Risk Myelodysplastic Syndromes (MDS)
    Montalban-Bravo, Guillermo
    Carcia-Manero, Guillermo
    Short, Nicholas J.
    Sasaki, Koji
    Sekeres, Mikkael A.
    Komrokji, Rami S.
    Steensma, David P.
    DeZern, Amy E.
    Roboz, Gail J.
    Kadia, Tapan
    Borthakur, Gautam
    DiNardo, Courtney
    Miller, Darla
    Estrov, Zeev
    Pemmaraju, Naveen
    Daver, Naval
    Konopleva, Marina
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Jabbour, Elias
    BLOOD, 2015, 126 (23)
  • [28] Sequential cytogenetic analysis of 322 patients with myelodysplastic syndromes.: Delineation of genetic evolution and clinical implications.
    Steidl, C
    Schabla, R
    Germing, U
    Hildebrandt, B
    Noesslinger, T
    Pfeilstocker, M
    Haas, P
    Lübbert, M
    Truemper, LH
    Haase, D
    BLOOD, 2004, 104 (11) : 651A - 651A
  • [29] Mitochondrial dysfunction in myelodysplastic syndromes.
    Reddy, PL
    Dar, S
    Anthwal, S
    Khan, M
    Patkar, K
    Rizvi, A
    Khan, T
    Azhar, O
    Nisar, D
    Shetty, VT
    Mundle, SD
    Alvi, S
    Galili, N
    Raza, A
    BLOOD, 2002, 100 (11) : 337B - 337B
  • [30] Telomere length in myelodysplastic syndromes.
    Boultwood, J
    Fidler, C
    Wainscoat, JS
    BLOOD, 1995, 86 (10) : 1325 - 1325
12345